Biopharma Investment Activity Continued to Rise in Q2: J.P. Morgan

Biopharma investment activity has been on the upswing so far in 2024, recovering from the downturn of the last few years. A new report from J.P. Morgan this month broke down the figures on how biopharma has done so far this year and found further evidence of a recovery.

The J.P. Morgan report noted that venture investments have returned, with “high-dollar rounds” entering the wider biopharma scene. It also stated that M&A activity had kept a “healthy pace” while the IPO market continued robustly.